I like to keep up on the biosimilar news and here's one I missed a couple days ago. Coherus and Baxter International have inked a $246 M deal for Coherus to develop an Enbrel biosimilar for Baxter to market. The front loaded deal -- by now normal -- calls for $30 M upfront payment with milestones that could total up to $210 M (God willing and the creek don't rise). Baxter will receive rights to market the drug in Europe, Canada and Brazil along with other emerging markets. Coherus has a previous deal to help Daiichi Sanyo to develop Enbrel for other Asian markets (exclusive of Japan). See Fierce Biotech.
Posted by Bruce Lehr Sep 4th 2013